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Abstract 
The effects of the antibiotics vancomycin (2 x 100 mg/kg/day) on the gut microbiota 
of female mice (outbred NMRI strain) were studied, in order to assess the relative 
contribution of the gut microbiome to host metabolism. The host’s metabolic 
phenotype was characterized using 1H NMR spectroscopy of urine and fecal extract 
samples. Time-course changes in the gut microbiotal community after administration 
of vancomycin were monitored using 16S rRNA gene PCR and denaturing gradient 
gel electrophoresis (PCR-DGGE) analysis and showed a strong effect on several 
species, mostly within the Firmicutes. Vancomycin treatment was associated with 
fecal excretion of uracil, amino acids and short chain fatty acids (SCFAs), highlighting 
the contribution of the gut microbiota to the production and metabolism of these 
dietary compounds. Clear differences in gut microbial communities between control 
and antibiotic-treated mice were observed in the current study. Reduced urinary 
excretion of gut microbial co-metabolites phenylacetylglycine and hippurate was also 
observed. Regression of hippurate and phenylacetylglycine concentrations against 
the fecal metabolite profile showed a strong association between these urinary 
metabolites and a wide range of fecal metabolites, including amino acids and SCFAs. 
Fecal choline was inversely correlated with urinary hippurate. Metabolic profiling, 
coupled with the metagenomic study of this antibiotic model, illustrates the close 
inter-relationship between the host and microbial “metabotypes”, and will provide a 
basis for further experiments probing the understanding of the microbial-mammalian 
metabolic axis. 
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INTRODUCTION 
The mammalian gut contains hundreds of species of commensal and symbiotic 
microbes, which mainly reside in the large intestine, and the caecum for rodents, 
where they contribute to ~60% of the total fecal mass produced.1,2 It is widely 
acknowledged that the presence of the gut microbiota is a key factor in gut 
development, structure and function.3-5 Intestinal microbiota may also play a major 
role in the etiology of many gut disorders, such as irritable bowel disease (IBD) and 
colon cancer.6,7 Moreover, the microbiome has recently been reported to vary 
significantly between obese individuals (human and animals) and normal individuals, 
and it is known to provide refined control mechanisms on energy recovery through 
catabolism of otherwise poorly digestible nutrients, i.e., resistant starch and other 
polysaccharides.8-10 Since the microbiota are extremely metabolically active and co-
metabolize many endogenous and xenobiotic compounds, they clearly have the 
potential to affect the biochemical composition of the tissues and biofluids of the 
host.11,12 
Previous research revealed the influence of the gut microbiota on the urinary 
metabolite composition in rodent studies using metabolic profiling methods based on 
1H nuclear magnetic resonance (NMR) spectroscopy.11-17 In particular, diet, 
medication and environmental-induced effects on aromatic components such as 
hippurate and 3-hydroxyphenylpropionic acid (HPPA), which are known to be 
generated or co-metabolized by gut microbiota, are well documented in conjunction 
with a variety of other metabolic pathways such as those involved with bile acid 
catabolism, choline metabolism and utilization of short chain fatty acids (SCFAs).11-17 
Further evidence of the direct contribution of the microbiota to host metabolism has 
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been obtained using metabolic profiling methods to characterize germ-free and 
antibiotic-rodent models.12,13,18,19 
Although germ-free models provide valuable information on microbial-
mammalian co-metabolism, acting in some respects as a “knock out”, it could be 
argued that, since the gut of such animals remains underdeveloped, they do not offer 
a true picture of ‘normal’ mammalian physiology and as such are not an optimal 
model for characterizing microbiota-mammalian metabolic interaction in ‘normal’ 
animals. An alternative approach is to employ conventional animals, with normal gut 
physiology, combined with antimicrobial treatment, which mimics more closely the 
actual environment of the host gut and its commensals. Indeed, from studies aimed 
at the deliberate reduction of the gut microbiota, as well as on the investigation of 
antibiotic-induced nephrotoxicity of pharmacological effects on the gut microbiota, a 
reduction in the urinary excretion of hippurate and other phenolic metabolites was 
evident.13,20,21 
As part of ongoing studies to determine the effect of the gut microbiota on host 
metabolic phenotypes, we employ here an antibiotic-based model to directly probe 
the dynamic effect of the microbiotal contribution to urinary and fecal composition. 
Additionally, we monitor time-course changes in the gut microbiota community during 
the course of the recovery using 16S rRNA gene polymerase chain reaction (PCR) 
and denaturing gradient gel electrophoresis (DGGE) analysis. For this, we have used 
vancomycin (a glycopeptide antibiotic,22 with broad activity against Gram-positive 
bacteria), which causes marked decrease in gut microbiotal populations in mice.23 
Vancomycin was chosen as a means of reducing the Gram-positive bacteria in the 
gut without overtly modifying the Gram-negative microbes, in order to target one 
particular aspect of the microbial influence on host metabolism. Additionally, 
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vancomycin is known to be poorly partitioned across the mammalian gastrointestinal 
mucosa and since it does not have systemic absorption, should not perturb host 
biochemistry directly.23 
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METHODS 
Two studies were initiated to assess effects of antibiotic treatments on host-gut 
metabolism. The initial exploratory study was used to monitor metabolic changes in 
the mouse at a single time point. A second study, hereafter referred to as the 
extension study, was carried out to ascertain the dynamic metabolic effects of 
antibiotic treatments in mice. 
 
Exploratory Study Design. This study was carried out at the animal care facilities of 
the Swiss Tropical Institute (Basel, Switzerland), and complied with Swiss local and 
national regulations on animal welfare (permission no. 2081). Twelve female (age: ~3 
weeks; weight: 20-25 g) outbred NMRI strain mice were purchased from RCC 
(Füllinsdorf, Switzerland). The animals were kept in groups of 3 in macrolonTM cages, 
and acclimatized for 7 days prior to the study under controlled environmental 
conditions (temperature: ~22ºC; relative humidity: ~70%; day/night cycle: 12-12 h). 
Mice were fed commercial rodent feed with water ad libitum. Six of the mice were 
dosed with vancomycin hydrochloride (2 x 100 mg/kg/day) on day 25 of the study for 
2 successive days. Mice were treated orally by gastric intubation with vancomycin 
suspended in 7% Tween-80 and 3% ethanol (volume 10 ml/kg body weight; serving 
as vehicle). The remaining six mice were given the vehicle only (10 ml/kg body 
weight), and hence served as controls. 
Fecal and urine sample collection was carried out 2 days after the initial 
dosing (i.e., day 27) between 09.00 and 11.00 hours. From each mouse, urine (at 
least 20 μl) and fecal samples (1-2 pellets) were collected into Petri dishes by gently 
stretching the mice or rubbing their abdomen. Samples were transferred into small 
microcentrifuge tubes, immediately frozen over dry ice and stored at -80ºC. 
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Extension Time-Course Study Design. A total of 20 NMRI female mice were 
purchased from RCC and divided into the control and vancomycin-treated groups 
with 10 mice each. Each mouse from the vancomycin treatment group was treated in 
the same way as the first study at 15-week-old, while mice from control group were 
administered 3 doses of drug vehicle only (age: 14 weeks). The 1-week difference in 
the age at the start of the experiment between this and the exploratory study can be 
ignored since mice are fully mature at this age and thus their microbial community 
would be fully established. Urine and stool samples for NMR experiments were 
collected from both groups at 1 day pre-dosing and days 1, 2, 3, 5, 7, 13, 19 after the 
final dosing and stored at -40°C. Stool samples for microbiological investigation were 
also collected at the same time points, fixed in 0.5 ml of 4% formalin, to which 9.5 ml 
of 70% (v:v) ethanol was added and stored at -20°C. 
 
Sample Preparation. Urine samples were prepared by mixing 20 μl of urine with 30 
μl of a phosphate buffer containing 90% D2O and 0.25 mM 3-trimethylsilyl-1-[2,2,3,3-
²H4] propionate (TSP) and left to stand for 10 min. The resulting mixtures were then 
transferred into 1.7 mm (outer diameter) NMR capillary tubes. 
Each fecal sample was homogenized with buffer (1 ml, 0.2 M sodium 
phosphate, pH 7.4). Homogenates were sonicated at ambient temperature (25°C) for 
30 min and centrifuged at 11000 g for 10 min. The supernatants (460 μl) were 
aliquoted and a final volume of 700 μl was made by the addition of 240 μl of TSP in 
90% D2O. These were further centrifuged at 11000 g for 10 min and 600 μl of the 
supernatant was pipetted into 5 mm NMR tubes. 
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1H NMR Spectroscopy. Spectra were obtained on a Bruker DRX600 spectrometer 
(Bruker Biospin; Rheinstetten, Germany) at 600.13 MHz (ambient probe temperature 
27°C). A standard 1-dimensional (1D) pulse sequence was used [recycle delay (RD)-
90o-t1-90o-tm-90o-acquire free induction decay (FID)]. The water signal was 
suppressed by irradiation during RD of 2 s, and mixing time (tm) of 150 ms. t1 was set 
to 3 μs and the 90o pulse length was adjusted to ~10 μs. For each sample, a total of 
64 transients (in exploratory study) and 256 transients (in the extension study) were 
accumulated into ~32,000 data points using a spectral width of 20 ppm. Prior to 
Fourier transformation, all FIDs were multiplied by an exponential function equivalent 
to a line broadening of 0.3 Hz. The assignment of the peaks to specific metabolites 
was based on 2-dimensional (2D) 1H-1H correlation spectroscopy (COSY) and 1H-1H 
total correlation spectroscopy (TOCSY) NMR, published literature,24,25 and statistical 
total correlation spectroscopy (STOCSY).26 
 
Data Processing and Analysis. 1H NMR spectra of fecal extract and urine samples 
were manually phased and baseline corrected using XwinNMR 3.5 (Bruker Biospin; 
Rheinstetten, Germany). The 1H NMR spectra were referenced to the TSP 
resonance at δ 0.0. The spectra were digitized using a MATLAB (version 7, The 
Mathworks Inc.; Natwick, MA, USA) script developed in-house. The region containing 
the water resonance was removed from each spectrum to eliminate baseline effects 
of imperfect water saturation. For each spectrum, normalization to the total sum of 
the residual spectrum was carried out on the data prior to pattern recognition 
analyses followed by scaling of the data to unit variance. 
Principal component analysis (PCA) was applied to the processed spectral 
data to reveal intrinsic treatment-related patterns within data as well as monitoring 
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the dynamic response of the mice to vancomycin intervention. Inter-animal variation 
can confound data interpretation, particularly in multivariate data of high 
dimensionality. Therefore, orthogonal-projection to latent structure discriminant 
analysis (O-PLS-DA)27 was performed in a MATLAB environment to optimally model 
class differences and to systematically identify metabolites contributing to the 
differences between the vancomycin-treated and control groups. The O-PLS-DA 
method decomposes the variation in X (NMR data) into 3 parts; the first being the 
variation in X related to Y (the class variable), and the last 2 containing the specific 
systemic variation in X and residual, respectively. The contribution of each metabolite 
to sample classification is interpreted using the O-PLS coefficients with back-scaling 
transformation, indicating the variable contributions to the antibiotic-induced 
discrimination in the models.28 Here, the colors projected onto the spectrum indicate 
the correlation of the metabolites discriminating vancomycin-treated mice from the 
corresponding controls. Red indicates a high correlation and blue denotes no 
correlation with sample class. The direction and magnitude of the signals relate to the 
covariation of the metabolites with the classes in the model. A coefficient of 0.71, 
corresponding to a 95% significance level, was used as a cut-off value to select 
variables that had a significant correlation with class and the model predictive 
performance (robustness) was evaluated using a 7-fold cross validation method.28 
Two of the 3 urinary metabolites that were most highly correlated with 
antibiotic ingestion, namely hippurate and phenylacetylglycine, were regressed 
against the total fecal metabolite profiles using O-PLS analysis based on the 
integrated hippurate resonance at δ 7.84, or the integrated phenylacetylglycine 
resonance at δ 7.43, as the Y or response matrix. The third metabolite, 
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guanidinoacetate, was not integrated due to substantial peak overlap, which would 
lead to inaccuracy in the calculation. 
 
Microbiological Analysis (PCR-DGGE Experiment). DNA Extraction. 
Approximately 0.2 g of stool sample was processed to remove preservation solution 
(2 washes with 0.5 ml PBS) and mixed with 1.4 ml of buffer ASL, the suspension was 
transferred into a plastic tube containing 1 g of 0.1 mm diameter zirconium/glass 
beads and vortexed for 1 min at maximum speed to ensure the sample was 
thoroughly homogenized. The DNA extraction was carried out using QIAamp DNA 
Stool Mini Kit (Qiagen, Dublin, Ireland) according to the manufacturer’s instructions. 
The 16S rRNA gene was amplified using a nested approach, the first PCR used 
primers 27f (5’ GAGTTTGATCMTGGCTCAG 3’) and 1492r (5’ 
GGYTACCTTGTTACGACTT 3’) and the second PCR was performed with 341fGC 
primers (5’ CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGTACG- 
GGAGGCAGCAG 3’) and 519r primers (5’ GTATTACCGCGGCTGGCTG 3’). DGGE 
analysis was performed as described elsewhere.30 A number of strong discriminatory 
DGGE bands were excised with a sterile pipette tip into sterile water, amplified and 
cleaned (QIAquick PCR Purification Kit, Qiagen, Dublin, Ireland) for the sequencing. 
The amplicon was purified (QIAquick PCR Purification Kit, Dublin, Ireland) and 
sequenced by GATC (Konstanz, Germany), phylogenetic analysis was performed 
using the RDP classifier tool.31 Additional PCR was performed using specific primers 
(Clostridium leptum sub-group or the C. coccoides sub-group) based on the 
extracted DNA and the PCR products were visualized on agarose gels by staining 
with ethidium bromide. 31 
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RESULTS 
Data obtained from both the exploratory and extension studies revealed consistent 
changes in the urinary and fecal metabolic profiles with the time course study 
generating further information on recovery of individual metabolites and the global 
profile after antibiotic intervention. The control and treated groups excreted drug 
vehicle (7% Tween / 3% ethanol) in their feces on day 1 but was eliminated within 48 
hours. No significant endogenous changes in metabolite profile were observed in the 
first 3 PCs. 
 
Vancomycin-Induced Effects on the 1H NMR Spectroscopic Profiles of Urine 
Samples. Typical examples of the 1H NMR spectra of urine obtained from an 
untreated and a vancomycin-treated mouse are shown in Figures 1A and 1B. 
Spectra from control mice were dominated by a number of metabolites, namely α-
ketoglutarate, α-ketoisocaproate, α-ketoisovalerate, n-butyrate, citrate, creatine, 
creatinine, dimethylamine, fumarate, glycine, hippurate, lactate, N-acetyl glycoprotein 
fragments, phenylacetylglycine, succinate, taurine, trimethylamine, and 
trimethylamine-N-oxide. Visual inspection of the spectra revealed marked differences 
in overall metabolic composition between urines obtained from untreated and 
vancomycin-treated mice, with the latter showing relatively lower concentrations of 
urinary phenylacetylglycine, hippurate and fumarate, and higher levels of urinary 
creatine, α-ketoisocaproate and α-ketoisovalerate. To examine the metabolic 
disturbance resulted from vancomycin in urine over all the time points, a PCA 
strategy was applied to the entire data set. A total of 3 principal components (PCs) 
were calculated for a PCA model using unit variance scaled spectral data shown in 
Figure 1C. There was clear separation between urine samples obtained from control 
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mice and mice given vancomycin 1-3 days after the final dosing. At days 5 and 7 
post-treatment, samples from treated mice were still differentiated but moved closer 
to the control cluster, finally co-mapping with the control cluster by day 13 post-
treatment. 
In addition to visually identified metabolites, O-PLS-DA (Figure 2) highlighted 
further discriminatory metabolites for the antibiotic-treated group, with vancomycin-
treated mice showing lower levels of urinary trimethylamine and trimethylamine-N-
oxide, and the higher levels of urinary n-butyrate, guanidinoacetic acid and N-acetyl 
glycoprotein fragments. However, Student’s t-tests of the urinary NMR data revealed 
that only guanidinoacetic acid and hippurate showed statistical significance at a 95% 
confidence interval. The model parameters for urine samples are given in Table 1 
together with the O-PLS-DA correlation coefficients indicating the relative 
contributions of key metabolites contributing to the antibiotic-perturbed profiles. 
In urinary O-PLS-DA plots comparing control and treated animals for each of 
the 7 time points, 3 dominant metabolites i.e., hippurate, phenalactyglycine (PAG) 
and creatine, were found to co-vary consistently during the course of the recovery 
from vancomycin treatment. The mean integrated signals for these metabolites 
relative to the total spectrum were calculated and plotted (Figure 2B). Urinary 
concentrations of both hippurate and PAG decreased after the vancomycin 
treatment. However, the “recovery” of hippurate towards control levels was slower 
(ca 19 days) than that of PAG (ca 7 days). Urinary creatine was increased at days 1 
and 2 post-vancomycin treatment and recovered from day 3 onwards. 
 
Vancomycin-Induced Effects on the Fecal Metabolite Profiles. Typical examples 
of the 1H NMR spectra of fecal extracts obtained from an untreated and a 
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vancomycin-treated mouse are shown in Figures 3A and 3B. A range of metabolites 
such as amino acids, SCFAs, uracil and succinate were also directly assigned in 
spectra from control and vancomycin-treated mice consistent with previously 
published data.16,17,24,25 Reduction in the relative concentrations of fecal amino acids, 
SCFAs and uracil, and an increase in fecal choline and oligosaccharide levels were 
observed in vancomycin-treated mice. The PCA plot of fecal samples collected over 
the entire study duration (Figure 3C) showed a similar metabolic movement to that 
observed for the urinary data. At days 1 and 3 post-vancomycin dosing, the fecal 
water composition was markedly different from that of controls. In terms of the 
number of perturbed metabolites, vancomycin showed a greater effect in faecal water 
than in urine. 
Systematic comparison of the treated and control groups using O-PLS 
generated strong models with goodness of fit, R2, of 98.3% and goodness of 
prediction,27,28 Q2, of 92.3%, and showed good discrimination in the scores plot 
(Figure 2), indicating that vancomycin caused a substantial and significant effect on 
the fecal composition as compared to the urinary changes. The O-PLS coefficients 
plot (Figure 4) confirmed the observed metabolic changes and also identified 
decreased levels of fecal lactate and succinate as significant discriminators of 
vancomycin treatment. The model parameters for fecal samples are given in Table 2, 
together with the O-PLS-DA correlation coefficients indicating the relative 
contributions of key metabolites contributing to the antibiotic-perturbed profiles. 
 The O-PLS-DA coefficient plot derived from spectra data of fecal water at day 
1 post-treatment (data not shown) showed a marked depletion of a range of amino 
acids including leucine, isoleucine, valine, lysine, glutamate, methionine, taurine and 
aromatic amino acids such as tyrosine, phenylalanine and cytosine, and SCFAs 
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(acetate, butyrate), together with other metabolites, such as 5-aminovalerate, 
succinate, nicotinurate and glucose. Moreover, increased concentrations of choline, 
oligossacharides and fumarate were also observed in the vancomycin-treated mice. 
All metabolites showed similar trend of changes during the course of treatment 
except 5-aminovalerate, which fluctuated and recovered back to “normal” level at day 
7 post-treatment. The relative concentrations of selected metabolites were calculated 
based on the integration of peaks, shown in Figure 4B. 
 
O-PLS Correlation of Urinary Hippurate and Phenylacetylglycine 
Concentrations with Fecal Metabolites. O-PLS regression of urinary hippurate 
against the fecal extract profiles (Figure 5A) generated a strong model (R2=92.9%, 
Q2=67.8% using a 1-component model with 1 orthogonal component). Several fecal 
amino acids were highly correlated with urinary hippurate concentrations, whilst 
SCFAs (propionate, n-butyrate and acetate) and uracil were also significantly 
positively correlated with urinary hippurate, albeit to a lesser extent. Conversely fecal 
choline and sugars were inversely correlated with urinary hippurate. Lactate and 
succinate were uncorrelated with hippurate. The regression model for urinary 
phenylacetylglycine (Figure 5B) showed correlations with the same molecules as 
hippurate but the model and correlation coefficients were weaker (R2=86.2%, 
Q2=41.1% using a 1-component model with 1 orthogonal component). Subsequent 
O-PLS regression analyses were carried out on all the time points (day 1-day 19) and 
the characteristics of these models are summarized in Table 3. The pattern of 
changes observed in these models were consistent, with decreasing Q2 at later time 
points, indicating weaker correlations between the fecal metabolic profiles and 
urinary hippurate and phenylacetylglycine concentrations. These findings are 
  - 16 -  
consistent with the changes observed in the quantified urinary metabolites (Figure 
2B). 
 
Microbial Diversity with Time and Trajectory of DGGE Data. 16S rRNA PCR-
DGGE and sequencing, as a routine molecular approach, was applied to examine 
disturbance of the microbiota caused by vancomycin treatment in mice over the 
duration of the extension study time course (19 days). Sequences closely related to 
C. leptum, C. coccoides, C. symbiosum and Photorhabdus luminescens were found 
to be impacted and were lost from the DGGE profiles 1 day post-treatment (Table 4). 
However, bands which were shown to be closely related to C. leptum and 
C. coccoides recovered at day 2 or day 3 post-treatment. 
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DISCUSSION 
Antibiotics alter the composition of the gut microbiota32 and play a central role in the 
development of C. difficile-associated colitis.33 Moreover the gut microbiota is 
resilient and once the antibiotic source has been removed, it is thought to 
substantially recover to its original composition and diversity.32 However, no work to 
date has shown how a major perturbation of the gut microbiota manifests itself in the 
host’s systemic metabolic phenotype, which is known to be partially under 
microbiome control.34 Metabolites synthesized via microbiome activity influence host 
biology and any dysbiosis in this virtual organ has implications for the host health. 
We undertook to correlate changes in the gut microbiota, induced by exposure to 
vancomycin, with the host’s metabonome35 and determine to what extent they are 
associated. 
Results obtained from the exploratory and extension studies revealed 
consistent changes in the urine and fecal metabolic profiles of mice after vancomycin 
treatment indicating that the vancomycin-induced effect on the microbiotal community 
was robust and reproducible. In the extension study, we demonstrated recovery from 
vancomycin treatment with individual metabolites showing differential recovery rates. 
We also showed clear differences in gut microbial communities between control and 
antibiotic-treated mice using PCR-DGGE-based microbiological methods. Since all 
animals were fed with the same food, kept in the same environment and given drug 
vehicle, it was unlikely that metabolic variation observed were due to environmental 
conditions. Vancomycin or its metabolites were not detected in any of the urine 
samples. This was expected since vancomycin does not cross through the intestinal 
lining; and since feces are excreted within 24 hours after treatment. However, drug 
vehicle was detected on day 1 from both groups and was eliminated within 48 hours. 
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Certain drug vehicles have been shown to effect urinary biochemical profiles. 
However, in a study conducted by Beckwith-Hall et al. (2002) Tween exerted the 
smallest effect on the metabolic profiles after saline consistent with the present 
study.36 The spectral regions affected by the vehicle were removed from the data set 
prior to mathematical modelling to minimise its effect on data analyses and 
interpretation of the metabolic data. 
Previous studies have highlighted the reduction in the urinary excretion of 
hippurate in both germ-free animals12 and in rats treated with antibiotics.13 After 
exposure to a standard laboratory environment, a dynamic series of changes in the 
biochemical composition of the urine was observed in germ-free animals, as reflected 
by sequential excretion of phenylacetylglycine, 4-hydroxyphenylpropionic acid, 3-
hydroxyphenylpropionic acid and, finally, hippurate at around 21 days post-exposure. 
Hippurate is a well described mammalian-microbial co-metabolite17,37 formed by 
glycine conjugation of benzoate (predominantly in the liver), which is produced from 
bacterial metabolism of plant phenols,38 or by intestinal microbiota in the presence of 
quinic acid (1,3,4,5-tetrahydroxycyclohexanecarboxylic acid).39 Depletion of hippurate 
has been previously reported after ingestion of antibiotics such as cephaloridine,19,20 
gentamicin,21 neomycin, tetracycline hydrochloride and bacitracin mixture.13 Gut 
microbiota also extensively catabolize protein and aromatic amino acids, including 
phenylalanine, tyrosine and tryptophan.40 Fecal amino acids, including tyrosine and 
phenylalanine, were noted to be directly correlated with urinary hippurate and 
phenylacetylglycine, consistent with decreased catabolism of these amino acids by 
the microbiota. In the current study vancomycin had a strong impact on the region of 
the spectrum representing phenolic molecules with particular effect on reduction of 
signals from hippurate and phenylacetylglycine. Both PAG and hippurate were 
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observed to be decreased after administration of vancomycin; however, urinary 
concentrations of PAG were restored to those of controls at day 5, while recovery of 
urinary hippurate was not experienced until the end of the experiment at day 19 post-
treatment. This suggests that establishment of a stable gut microbiota requires a 
similar time frame in both conventionalisation of germ-free rats and in conventional 
mice after vancomycin treatment. Such a 19-day recovery of hippurate may reflect a 
delayed re-population of hippurate-producing microbiota compared with other 
microbiota. 
Other urinary indicators of vancomycin-perturbed microbiota included relative 
decrease in the concentrations of trimethylamine (TMA), a gut bacterial product of 
the choline metabolism, and trimethylamine-N-oxide (TMAO), a product of its hepatic 
detoxification.41,42 Choline metabolism is a complex host-symbiont molecular 
interaction which involve both mammalian and symxenobiotic (metabolite with dietary 
and/or gut microbiota origin) metabolic pathways.16 Although vancomycin treatment 
did not significantly alter the choline and methylamine content of fecal extracts, a 
trend towards decreased level of choline in fecal water from vancomycin-treated mice 
was observed at day 1 post-dosing. The variations of TMA and choline were not 
observed from day 3 onwards. This might indicate that choline metabolism is 
influenced by both vancomycin and non-vancomycin sensitive bacteria. In addition, 
methylamines are known to be co-metabolized by the host and the gut microbiota in 
the large intestine.42 
Bacterial fermentation of carbohydrates in the caecum and the large intestine 
leads to the production of SCFAs and lactic acid depending on the bacterial strains 
involved.43-46 We observed lower amounts of fecal acetate, n-butyrate, propionate 
and lactate, and increased quantities of fecal oligosaccharides in mice treated with 
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vancomycin compared to controls (Table 1), suggesting disruption in carbohydrate 
fermentation due to vancomycin-induced changes in gut microbial populations. Our 
observations are consistent with previous in vitro experiments using porcine caecal 
contents to create an in vitro model of gut microbial metabolism which showed 
marked decrease of fecal SCFAs following vancomycin intervention.47 In particular, 
fermentation of carbohydrates by the Bifidobacteria normally induces a decrease in 
the pH of the caecal content associated quantitatively with different SCFA profiles of 
treated animals as compared to control animals, which inhibits the growth of 
pathogens.45,48 The disruption of the microbial production of SCFAs after vancomycin 
administration might thus be expected to profoundly disturb the gut microbial 
environment and alter relative amounts, and composition of colonic bacterial 
species.48 Given that, most of the SCFAs are rapidly absorbed in the ascending part 
of the colon and represent potential substrates for the liver and various tissues such 
antibiotic-induced effects might have significant nutritional consequences for the 
host.45,49,50 The disruption of the SCFA bacterial metabolism results in a loss of 
bioavailability of these metabolites for the host metabolism, possibly related to the 
observed reduction in urinary elimination of n-butyrate and α-ketoisovalerate (Table 
2). In addition, the reduction in n-butyrate production might have physiological 
consequences for individual animals because bacterial n-butyrate has a ‘trophic’ 
effect on colonocytes.2,45 Previous studies have shown the contribution of gut 
microbiota to mammalian host metabolism by measuring specific groups of 
compounds such as amino acids, bile acids, SCFAs, monitoring changes in fecal 
ammonia and host physiological descriptors such as those related to energy 
expenditure, lipoprotein profile and recovery from gut dysbiosis.51-53 Interestingly, 
fecal lactate did not correlate with urinary hippurate (Figure 5a) and may reflect the 
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fact that urinary lactate contains both the D- and L-enantiomers, of mixed host and 
microbial sources whereas fecal lactate is predominantly produce by bacteria and 
therefore is mainly in the D- form. 
Another prominent finding is the reduction in the concentrations of SCFAs 
including acetate and butyrate, together with increased concentrations of 
oligosaccharides in faecal water from vancomycin-treated mice compared with that 
from control mice on days 1, 3, 5 and 7. This is consistent with a previous study 
where Bender et al. (2001) employed an in vitro model for the semi-continuous 
incubation of defined colon contents to examine the effect of vancomycin on SCFAs 
composition.47 These SCFAs are derived from the fermentation of non-gastric-
digestible starches and oligosaccharides by saccharolytic bacteria. The composition 
of fermentation end-products is dependent on the bacteria species, substrates and 
chemical environment, such as pH.48 Rycroft et al. (2001) reported that galacto-
oligosaccharides generated high levels of SCFAs and decreased the numbers of 
clostridia.54 Among these SCFAs, n-butyrate seems to be most beneficial to colon 
cellular functions, such as proliferation, membrane synthesis and sodium absorption 
growth, and it also shows effect of anti-colon carcinogenesis and anti-tumour 
activity.55,56 In the present study, the ‘abnormal’ levels of SCFAs, which lasted for 13 
days, indicated a large amount of microbiota experienced reduced activities, unlike 
C. coccoides and C. leptum which recovered from day 2 onwards. Interestingly, there 
was an increase in species diversity in the vancomycin-treated group supported by 
the increased number of DNA bands appearing on the DGGE gels. Although those 
species could not be unequivocally identified here, this gross observation is in 
agreement with a previous human study,53 which reported a marked elevation in total 
numbers of Clostridium bacteria including C. bifermentans, C. clostridioforme, 
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C. sordellii and C. malenominatum, and an increased species diversity in the elderly 
people under antibiotic treatment. 
In the current study lower fecal concentration of amino acid levels were 
observed in vancomycin-treated mice (Table 1, Figure 4), which may affect the 
complex fluxes of amino acids and protein nitrogen across the intestinal mucosa.57 
Although gastrointestinal digestion of some dietary proteins is incomplete, only about 
2-5% escapes small intestinal digestion/absorption. Immense populations of bacteria 
living within the large intestine are key contributors to the digestion and metabolism 
of amino acids and vitamins in the gut.58 In particular, intestines in germ-free animals 
generally show changed gut morphology, including atypical epithelial structure, less 
efficient nutrient usage, and intestinal inflammation.59-61 The antibiotic-induced 
disruption of the gut bacterial ecology may thus promote an inflammatory disruption 
of absorptive abilities of intestinal brush border, which could lead to malabsorption of 
amino acids and SCFAs.62 Additionally, since > 50% of the fecal mass generally 
consists of bacteria,2 it is conceivable that the amino acids extracted from feces 
might also be derived from the gut bacteria themselves and that the observed 
reduction in fecal amino acids reflects perturbed amino acids metabolism as well as 
reduced bacterial population due to vancomycin treatment. 
Changes were noted in urinary α-ketoisocaproate and creatine levels following 
antibiotic treatment. In the human gut, the anaerobic genus Clostridium were found to 
metabolize leucine to isocaproate and α-ketoisocaproate63; and creatine has been 
shown to be co-metabolized in mammals and their gut microbiota.64,65 Perturbed gut 
microbial changes observed in SCFAs, oligosaccharides and amino acids indicated 
vancomycin-induced changes in metabolism of these compounds, which may also 
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explain the change in the relative amounts of α-ketoisocaproate and creatine in the 
urine.  
This work has shown the potential of a metabolic profiling strategy for studying 
the effects of antibiotics on the gut microbiota and has provided insights into the 
metabolic changes associated with antibiotic treatment and its effect on gut 
microbiota modification. Furthermore, urinary hippurate levels correlated closely with 
the amino and SCFA profiles in the feces. Our metabolic profiling approach showed 
changes in host amino acids metabolism and SCFA metabolism as well as in host 
metabolism of phenolics due to antibiotic treatment. The methods used here were 
intended to look at general aspects of the gut microbiome and as such are not 
specific enough to determine which species are being altered and may be 
responsible for the changes in the host’s metabolite profiles. Further studies using 
such methods as stable isotope probing, metabonomics and high-throughput 
sequencing of 16S rRNA genes are needed to start to determine the keystone 
species in the gut, which are responsible for generating the host’s metabotype. 
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Figure Legend: 
 
Figure 1. Typical 600 MHz 1H NMR spectra of urine obtained from untreated mice 
(A), and vancomycin-treated mice (B) 2 days after the final dosing. (C) PCA trajectory 
plots of urine. Color code: grey (control), black (vancomycin-treated d-1), red (d1), 
green (d2), yellow (d3), blue (d5), purple (d7), dark blue (d13 & d19). 
Keys: 5, lactate; 7, acetate; 14, succinate; 17, taurine; 18, glycine; 22, α-
ketoisocaproate; 23, butyrate; 24, α-ketoisovalerate; 25, N-acetyl glycoproteins 
(NAG); 26, pyruvate; 27, α-ketoglutarate; 28, dimethylglycine; 29, dimethylamine; 30, 
trimethylamine; 31, creatine; 32, creatinine; 33, trimethylamine-N-oxide (TMAO); 34, 
guanidoacetic acid (GAA); 35, hippurate; 36, fumarate; 37, phenylacetylglycine; 38, 
citrate. 
 
Figure 2. (A) O-PLS-DA scores and coefficient plots derived from the 1H NMR 
spectra of urine indicating discrimination between untreated and vancomycin-treated 
mice 2 days after the final dosing. The color code corresponds to the correlation 
coefficients of the variables. For metabolites identification key, please see Figure 1 
caption. (B) Integration of selected peaks from hippurate, creatine and PAG in total 
area-normalised urinary spectra at all time points, demonstrating the concentrations 
of metabolites varied as the time progressed. Error bars represent the standard error. 
 
Figure 3. Typical 600 MHz 1H NMR spectra of fecal extracts obtained from untreated 
mice (A), and vancomycin-treated mice (B) 2 days after the final dosing. (C) PCA 
trajectory plots of fecal water. Color code: grey (control), black (vancomycin-treated 
d-1), red (d1), yellow (d3), blue (d5), purple (d7), dark blue (d13 & d19). 
Keys: 1, isoleucine; 2, leucine; 3, valine; 4, propionate; 5, lactate; 6, alanine; 7, 
acetate; 8, glutamate; 9, aspartate; 10, asparagine; 11, methionine; 12, lysine; 13, 
arginine; 14, succinate; 15, glutamine; 16, choline; 17, taurine; 18, glycine; 19, uracil; 
20, tyrosine; 21, phenylalanine; 23, butyrate. 
 
Figure 4. (A) O-PLS-DA scores and coefficient plots derived from the 1H NMR 
spectra of fecal extract indicating discrimination between untreated and vancomycin-
treated mice 2 days after the final dosing. The color code corresponds to the 
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correlation coefficients of the variables. For metabolite identification key, see Figure 3 
caption. (B) Integration of selected peaks from acetate, butyrate and 5-aminovalerate 
in total area-normalised faecal water spectra for all time points, demonstrating the 
concentrations of metabolites varied as the time progressed. Error bars represent 
standard error. 
Key: * Vancomycin vehicle peak did not contribute to the separation of the 2 classes 
of animal and was therefore removed from the analysis (inset). 
 
Figure 5. O-PLS regression of (A) urinary hippurate and (B) urinary 
phenylacetylglycine against the fecal extract 1H NMR spectra profiles. 
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Table 1. Metabolic effects of vancomycin treatment on feces of mice 
 
 
 
Untreated vs. 
vancomycin-treated 
(correlation coefficient) 
Metabolites Chemical shift 
Faeces 
Q2 = 0.92 
R2 = 0.98 
acetate 1.92 (s) +0.88 
alanine 1.48 (d) +0.97 
arginine 1.63 (m) +0.96 
asparagine 2.94 (m) +0.82 
aspartate 2.79 (m) +0.90 
n-butyrate 0.90 (t) +0.86 
choline 3.23 (s) -0.69 a 
glutamate 2.08 (m) +0.91 
glycine 3.56 (s) +0.65 a 
isoleucine 1.02 (d) +0.95 
lactate 1.32 (d) +0.48a 
leucine 0.96 (t) +0.94 
lysine 1.72 (m) +0.95 
methionine 2.13 (s) +0.93 
oligosaccharides 3.5 - 4.0 -0.90 
phenylalanine 7.40 (t) +0.95 
propionate 2.19 (q) +0.90 
taurine 3.46 (t) +0.81 
tyrosine 6.87 (dd) +0.89 
uracil 5.81 (d) +0.91 
valine 1.04 (d) +0.94 
 
Key: a Shows trend but not significant at the level of P<0.05 
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 Table 2. Metabolic effects of vancomycin treatment on urine of mice 
 
 
 
Untreated vs. 
vancomycin-treated 
(correlation coefficient) 
Metabolites Chemical shift 
Urine 
Q2 = 0.75 
R2 = 0.98 
α-ketoisovalerate 1.13 (d) -0.64 a 
n-butyrate 0.90 (t) -0.58 a 
creatine 3.93 (s) -0.60 a 
creatinine 4.06 (s) -0.45a 
GAA 3.80 (s) -0.75 
glycine 3.56 (s) -0.47a 
hippurate 7.84 (d) +0.86 
NAG 2.06 (s) -0.64 a 
phenylacetylglycine 7.43 (m) +0.67 a 
taurine 3.46 (t) +0.49a 
TMA 2.89 (s) +0.55 a 
TMAO 3.27 (s) +0.50 a 
 
Key: a Shows trend but not significant at the level of P<0.05; GAA, guanidoacetic 
acid; NAG, N-acetyl glycoproteins; TMA, trimethylamine; TMAO, trimethyl-N-oxide 
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Table 3. O-PLS model summary of the correlations between urinary hippurate 
and phenylacetylglycine with fecal metabolites for day 1 (D1), day 3 (D3), day 7 
(D7), day 13 (D13) and day 19 (D19) 
 hippurate PAG 
Time point Q2 R2 Number of components Q
2 R2 Number of components
D1 71% 57% 1 <0 - - 
D3 56% 64% 3 37% 60% 2 
D7 63% 64% 5 13% 20% 1 
D13 52% 38% 3 <0 - - 
D19 17% 22% 1 <0 - - 
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Table 4. Taxonomic affiliation of the partial 16S rRNA gene sequence obtained from the excised DGGE band. The rows shaded in 
grey are the closest hits to bacteria, which have been cultured 
Phyla Class Order Family Genus Species Accesion number Similarity (%) 
Firmicutes Mollicutes Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Uncultured bacterium AY960576 92 
Firmicutes Mollicutes Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Anaeroplasma bactoclasticum M25049 90 
Firmicutes Mollicutes Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Uncultured bacterium EU006469 92 
Firmicutes Clostridia Clostridiales Eubacteriaceae Eubacterium Eubacterium desmolans L34618 83 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Uncultured bacterium EF406679 97 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Clostridium cocleatum AF028350 97 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Uncultured bacterium EF603657 97 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Clostridium sp. BA-1 AB196728 83 
Firmicutes Clostridia Clostridiales Lachnospiraceae Incertae sedis Uncultured bacterium EF704431 96 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium Clostridium symbiosum EF442669 95 
Firmicutes Clostridia Clostridiales Clostridiaceae Ruminococcus Uncultured bacterium AY976513 58 
Firmicutes Clostridia Clostridiales Lachnospiraceae Anaerostipes butyrate-producing bacterium SS2/1 AY305319 60 
Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Escherichia Uncultured bacterium EF674507 94 
Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae Photorhabdus Photorhabdus luminescens DQ518589 93 
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Metabolic profiling of antibiotic model illustrates the close inter-relationship 
between the host and microbial “metabotypes”, and provides a basis for further 
experiments to probe and understand the complex microbial-mammalian 
metabolic axis. This work has shown the potential of metabolic profiling tools, 
coupled with microbiological analysis, for studying the effects of antibiotics on the 
gut microbiota and has provided insights into the metabolic changes associated 
with antibiotic treatment and its effect on gut microbiota modification. 
